Neuroplasticity and schizophrenia

Biological Psychiatry

Volumn 56, Issue 8, 2004, Pages 540-543

  Frost, Douglas O ^a,b   Tamminga, Carol A ^b,e   Medoff, Deborah R ^a   Caviness, Verne ^c   Innocenti, Georgio ^d   Carpenter, William T ^b  

^a Dept Pharmacol and Exp Therapeut ^*  (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

BDNF; course of illness; glutamate; neurodevelopmental; plasticity; Schizophrenia

Indexed keywords

CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL RESEARCH; DISEASE COURSE; HUMAN; LEARNING; MEDICAL INFORMATION; MEMORY; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANIMALS; HUMANS; MODELS, NEUROLOGICAL; NEURONAL PLASTICITY; SCHIZOPHRENIA;

EID: 5044228028     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.01.020     Document Type: Review

References (56)

1. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E. Jr, Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry. 52:1995;258-266
2. Andreasen N.C. Symptoms, signs, and diagnosis of schizophrenia. [review] Lancet. 346:1995;477-481
3. Arnold S.E., Lee V.M., Gur R.E., Trojanowski J.Q. Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. Proc Natl Acad Sci U S A. 88:1991;10850-10854
4. Bachevalier J. Medial temporal lobe structures and autism A review of clinical and experimental findings. Neuropsychologia. 32:1994;627-648
5. Bachevalier J., Malkova L., Mishkin M. Effects of selective neonatal temporal lobe lesions on socioemotional behavior in infant rhesus monkeys (Macaca mulatta). Behav Neurosci. 115:2001;545-559
6. Barnes T.R., Liddle P.F. Evidence for the validity of negative symptoms. [Review] Mod Probl Pharmacopsychiatry. 24:1990;43-72
7. Bellack A.S., Mueser K.T., Morrison R.L., Tierney A., Podell K. Remediation of cognitive deficits in schizophrenia. Am J Psychiatry. 147:1990;1650-1655
8. Bellack A.S., Weinhardt L.S., Gold J.M., Gearon J.S. Generalization of training effects in schizophrenia. Schizophr Res. 48:2001;255-262
9. Benes F.M. Myelination of cortical-hippocampal relays during late adolescence. Schizophr Bull. 15:1989;585-593
10. Berman K.F. Cortical "stress tests" in schizophrenia Regional cerebral blood flow studies. Biol Psychiatry. 22:1987;1304-1326
11. Bibel M., Barde Y. Neurotrophins Key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 14:2000;2919-2937
12. Boulanger L.M., Huh G.S., Shatz C.J. Neuronal plasticity and cellular immunity Shared molecular mechanisms. Curr Opin Neurobiol. 11:2001;568-578
13. Carpenter W.T. Jr, Buchanan R.W. Schizophrenia. N Engl J Med. 330:1994;681-690
14. Cavelier L., Jazin E.E., Eriksson I., Prince J., Bave U., Oreland L., Gyllensten U. Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics. 29:1995;217-224
15. Ciompi L., Muller C. [Lifestyle and age of schizophrenics. A catamnestic long-term study into old age.]. [In German] Monogr Gesamtgeb Psychiatr Psychiatry Series. 12:1976;1-242
16. Clementz B.A., McDowell J.E., Zisook S. Saccadic system functioning among schizophrenia patients and their first-degree biological relatives. J Abnorm Psychol. 103:1994;277-287
17. Dierks T., Linden D.E., Jandl M., Formisano E., Goebel R., Lanfermann H., Singer W. Activation of Heschl's gyrus during auditory hallucinations. Neuron. 22:1999;615-621
18. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res. 52:2001;79-86
19. Eastwood S.L., Harrison P.J. Hippocampal and cortical growth-associated protein-43 messenger RNA in schizophrenia. Neuroscience. 86:1998;437-448
20. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66 met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 112:2003;144-145
21. Erlenmeyer-Kimling L., Rock D., Squires-Wheeler E., Roberts S., Yang J. Early life precursors of psychiatric outcomes in adulthood in subjects at risk for schizophrenia or affective disorders. Psychiatry Res. 39:1991;239-256
22. Freiwald W.A., Kreiter A.K., Singer W. Synchronization and assembly formation in the visual cortex. Prog Brain Res. 130:2001;111-140
23. Frith C.D., Friston K.J., Herold S., Silbersweig D., Fletcher P., Cahill C., et al. Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br J Psychiatry. 167:1995;343-349
24. Frost D.O. BDNF/trkB signaling in the developmental sculpting of visual connections. Prog Brain Res. 134:2001;35-49
25. Frost D.O., Cadet J.L. Effects of methamphetamine-induced neurotoxicity on the development of neural circuitry A hypothesis. Brain Res Brain Res Rev. 34:2000;103-118
26. Gao X.M., Sakai K., Roberts R.C., Conley R.R., Dean B., Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus Effects of schizophrenia. Am J Psychiatry. 157:2000;1141-1149
27. Gottesman I.I., Shields J. Schizophrenia The Epigenetic Puzzle. 1982;Cambridge University Press, New York
28. Guidotti A., Auta J., Davis J.M., Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder A postmortem brain study. Arch Gen Psychiatry. 57:2000;1061-1069
29. Harding C.M., Brooks G.W., Ashikaga T., Strauss J.S., Breier A. The Vermont longitudinal study of persons with severe mental illness, I Methodology, study sample, and overall status 32 years later. Am J Psychiatry. 144:1987;718-726
30. Harding C.M., Brooks G.W., Ashikaga T., Strauss J.S., Breier A. The Vermont longitudinal study of persons with severe mental illness, II Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry. 144:1987;727-735
31. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 122:(Pt 4):1999;593-624
32. Harvey P.D., Lenzenweger M.F., Keefe R.S., Pogge D.L., Serper M.R., Mohs R.C. Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients Formal thought disorder. Psychiatry Res. 44:1992;141-151
33. Holcomb H.H., Lahti A.C., Medoff D.R., Weiler M., Dannals R.F., Tamminga C.A. Brain activation patterns in schizophrenic and comparison volunteers during a matched-performance auditory recognition task. Am J Psychiatry. 157:2000;1634-1645
34. Knable M.B., Weinberger D.R. Are mental diseases brain diseases? The contribution of neuropathology to understanding of schizophrenic psychoses. Eur Arch Psychiatry Clin Neurosci. 245:1995;224-230
35. Kung L., Roberts R.C. Mitochondrial pathology in human schizophrenic striatum A postmortem ultrastructural study. Synapse. 31:1999;67-75
36. Lahti A.C., Holcomb H.H., Medoff D.R., Weiler M.A., Tamminga C.A., Carpenter W.T. Jr. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiatry. 158:2001;1797-1808
37. Liddle P.F. The symptoms of chronic schizophrenia A re-examination of the positive-negative dichotomy. Br J Psychiatry. 151:1987;145-151
38. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., Gilmore J. The early stages of schizophrenia Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 50:2001;884-897
39. Manji H.K., Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders Implications for the development of novel therapeutics. Psychopharmacol Bull. 35:2001;5-49
40. McNamara J.O. Emerging insights into the genesis of epilepsy. Nature. 64:1999;A15-A22
41. Middleton F.A., Mirnics K., Pierri J.N., Lewis D.A., Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci. 22:2002;2718-2729
42. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 28:2000;53-67
43. Neville H.J., Bavelier D. Neural organization and plasticity of language. Curr Opin Neurobiol. 8:1998;254-258
44. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry. 47:1990;1023-1028
45. Pascual-Leone A., Hamilton R., Tormos J.M., Keenan J.P., Catala M.D. Neuroplasticity in the adjustment to blindness. Grafman J., Christen Y. Building a Bridge from the Laboratory to the Clinic. 1999;93-108 Springer-Verlag, New York
46. Poo M.M. Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2:2001;24-32
47. Sadato N., Pascual-Leone A., Grafman J., Ibanez V., Deiber M.P., Dold G., Hallett M. Activation of the primary visual cortex by Braille reading in blind subjects. Nature. 380:1996;526-528
48. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis A circuit based model of schizophrenia. Biol Psychiatry. 45:1999;17-25
49. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry. 52:1995;805-818
50. Sestan N., Artavanis-Tsakonas S., Rakic P. Contact-dependent inhibition of cortical neurite growth mediated by notch signaling. Science. 286:1999;741-746
51. Spence S.A., Liddle P.F., Stefan M.D., Hellewell J.S., Sharma T., Friston K.J., et al. Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk. Focal dysfunction and distributed disconnectivity reappraised. Br J Psychiatry. 176:2000;52-60
52. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry. 5:2000;293-300
53. Tamminga C.A., Thaker G.K., Medoff D.R. Neuropsychiatric aspects of schizophrenia. Yudofsky S.C., Hales R.E. The American Psychiatric Publishing Textbook of Neuropsychiatry and Clinical Neurosciences. 2001;1051-1086 American Psychiatric Press, Washington, DC
54. Temple E., Deutsch G., Poldrak R., Miller S., Tallal P., Merzenich M.M., Gabrieli J.D. Neural deficits in children with dyslexia ameliorated by behavioral remediation Evidence from functional MRI. Proc Natl Acad Sci U S A. 100:2003;2860-2865
55. Thaker G.K., Ross D.E., Gold J.M., Blaxton T.A. Model of smooth pursuit eye movement function in schizophrenia. Schizophr Res. 36:1999;267
56. Weickert C.S., Webster M.J., Hyde T.M., Herman M.M., Bachus S.E., Bali G., et al. Reduced GAP-43 mRNA in dorsolateral prefrontal cortex of patients with schizophrenia. Cereb Cortex. 11:2001;136-147